Background: Patients with acute lymphocytic leukemia (ALL) and those with lymphoblastic lymphoma (LBL) have overlapping clinical and immunophenotypic features and they have been treated with the same or very similar chemotherapy regimens. The goal of this multi-institutional phase II trial was to evaluate the therapeutic efficacy of a short-term, six-drug chemotherapy regimen for adult patients with untreated ALL or LBL.
INTRODUCTION
Acute lymphocytic leukemia (ALL) and lymphoblastic lymphoma (LBL) have overlapping clinical and cytological features such as a mediastinal mass, leukemic manifestation, a high prevalence of central nervous system (CNS) involvement, a high incidence in young males and the convoluted morphology of lymphoblasts, among other features (1) . ALL is immunophenotypically categorized as being of immature B-or T-cell lineage and T-ALL and T-LBL show similar immunophenotypes of a thymocyte origin (2) . Based on these common characteristics, patients with ALL and those with LBL have been treated with the same or very similar chemotherapy regimens (1, (3) (4) (5) and show similar survival curves (1, 4) . Generally, the prognoses of adult patients with these diseases are poor compared with those of pediatric patients (6) (7) (8) (9) (10) (11) (12) (13) .
In 1981, the Lymphoma Study Group of the Japan Clinical Oncology Group (JCOG-LSG) started a nationwide randomized trial for non-Hodgkin's lymphoma including LBL, using the first-generation combination chemotherapy, VEPA [vincristine (VCR), cyclophosphamide (CPM), prednisolone (PSL) and doxorubicin (DXR)] or VEPA-M [VEPA plus methotrexate (MTX)]. However, the outcome of this treatment was poor for LBL (14, 15) .
With the aim of improving the poor results of the previous chemotherapy programs conducted by the JCOG-LSG against LBL, we designed an alternating non-cross-resistant combination chemotherapy consisting of VEPA, l-asparaginase (I-asp) and intermediate-dose MTX for patients with ALL and those with LBL.I-Asp and MTX have antitumor mechanisms (16) which are different from those of the VEPA agents.
The conventional maintenance therapy with daily 6-mercaptopurine (6-MP) and weekly MTX, usually given for 24 months or longer, has been incorporated in many chemotherapy programs against ALL and LBL (3,6,8-13); however, its efficacy in adult ALL and LBL patients has never been addressed by randomized trials. One of the aims of this multi-institutional phase II study was to investigate whether this short-term, simplified combination chemotherapy without the traditional maintenance therapy would result in patient outcomes comparable to those of the studies including long-term maintenance therapy (17) (18) (19) .
PATIENTS AND METHODS

PATIENTS
ALL and LBL were diagnosed according to the French-American-British (FAB) Classification (20, 21) and Working Formulation (22) , respectively at each institution. Patients with LBL at any Ann Arbor clinical stage (23) were eligible. Patients with the following disorders were ineligible: performance status (PS) <40% (Kamovsky) or PS 4 [World Health Organization (~O)] (24), liver dysfunction (liver cirrhosis or hepatic transaminase >2x upper limits of normal range), renal function impairment (serum creatinine >2.0 mg/dl), severe infection, cardiac failure, cardiac disorders which may be worsened by the administration of anthracyclines, active concurrent cancer or other severe complications. Patients who had received anticancer agents at the time of entry were ineligible, but those receiving radiation therapy or glucocorticoids without chemotherapy were eligible. A lumbar puncture for a cerebrospinal fluid examination was recommended at diagnosis. Patients with symptomatic CNS involvement were not excluded but received additional CNS therapy.
Immunophenotyping was performed at each institution and the data obtained were used in the central pathology review. A flow cytornetric analysis with a panel of monoclonal antibodies was conducted as an immunofluorescent assay on suspended cells. At least 10 monoclonal antibodies against major leukocyte differentiation antigens [CD2, CD3, CD4, CD7, CD8, CDI0, CDI3, CDI9, CD20, human leukocyte antigen-D-related (HLA-DR), etc.] and assays for terminal deoxynucleotidyl transferase (TdT), surface membrane immunoglobulin (Sm-Ig) and cytoplasmic immunoglobulin (C-Ig) were recommended. Samples were considered to be positive for each monoclonal antibody if more than 20% of cells showed specific labeling above that of controls. The B-lineage phenotype was defined as CD 19+ or CD20+; and the T-lineage phenotype as CD2+, CD5+ or CD7+. Cases expressing Sm-Ig were categorized as mature B-cell phenotype. Patients with myeloperoxidase-negative blasts that expressed only myeloid antigens (and not B-or T-Iymphoid antigens) were reclassified as acute myelocytic leukemia (AML), subtype MO and were deemed to be ineligible (one patient). For the biopsied lymph node or tumor samples, an immunohistochemical analysis using monoclonal antibodies was conducted. Even if the biopsied specimen showed histological findings compatible with LBL, the patients having 30% tumor cells or more in their bone marrow (BM) were diagnosed as having ALL. It was recommended that a pretreatment peripheral blood (PB), BM or biopsied specimen be subjected to a gene rearrangement analysis of immunoglobulin gene and T-cell receptor gene and a cytogenetic analysis. PB and BM smears or sections of the biopsied specimens of the enrolled patients were reviewed by the central review committee.
The protocol was approved by the Clinical Trial Review Committee of the JCOG and the institutional review board at each participating institution. Before treatment, informed consent was obtained from each patient. TREATMENT 
REGIMENS
The treatment regimens consisted of two courses ofVEPA-L and four courses of M-VEPA (Table 1) *100 mg/m-IV bolus followed by 300 mg/m-drip infusion for 4 h. For non-leukemic cases, when the granulocyte count was <1500/~1 or when the platelet count was <100 OOO/~l, VEPA-L and M-VEPA were postponed until the count recovered. When the platelet count was <70 000/~1 or when the granulocyte count was <1000/~1, the combination of VCR, CPM and PSL was omitted and the combination of VCR, CPM, DXR and PSL was postponed during each course. In all patients, MTX was omitted when the creatinine clearance was <60 ml/min. Treatment was postponed if the serum glutamic oxaloacetic transaminase (GOT) level was> 100 U or the total bilirubin was >2.0 mg/dl. MTX was omitted or postponed when the serum GOT was more than two times higher than the normal upper range or if the total bilirubin was above the normal upper limit. DXR was omitted when DXR-induced cardiotoxicity (tachycardia, arrhythmia or ejection fraction <50%) occurred. The total dose ofDXR was kept at 480 mg/m-'. PSL was omitted in patients with diabetes mellitus. Patients who had an episode of severe infection due to leucocytopenia during remission received 25% reduced doses of CPM and DXR thereafter. To prevent interstitial pneumonia, an arterial blood gas analysis was performed and when the arterial blood oxygen concentration (Pa02) was <70 mmHg, CPM and MTX were omitted. Patients with ALL were considered to achieve complete remission (CR) when the results of a BM examination became normal (blasts <5%) along with the normalization of all abnormal laboratory findings and all extramedullary diseases had resolved and these responses lasted for at least 4 weeks. Patients with LBL were judged to achieve CR when the tumor or swollen lymph nodes disappeared for more than 4 weeks, according to the WHO response criteria (24) .
ASSESSMENT OF TOXICITIES
Toxicity was assessed according to the WHO toxicity criteria (24) .
STATISTICAL ANALYSIS
All analyses were performed using SAS statistical software (SAS for Windows, Version 6.12, SAS Institute, Cary, NC). All values are based on two-sided tests. The CR rate, survival and disease-free survival (DFS) were evaluated in 46 eligible cases. Fisher's exact test was used to assess the association between CR rate and each patient characteristic. Survival was calculated from the date of the beginning of chemotherapy to the last follow-up date or death. The duration of DFS was defined to be the time from achieving CR to relapse (BM, PB or CNS), death or date oflast follow-up. Survival curves were obtained by the Kaplan-Meier product limit method (25) . The difference between survival curves according to each demographic and clinical feature was tested using the log-rank test. The LIFETEST procedure of SAS software was used for the Kaplan-Meier method and the log-rank test (26) . Cox proportional hazards regression analysis was performed to assess the association between each clinical patient characteristic and survival using the PHREG procedure (27) . The analysis was based on all data available as of August 15, 1996 .
RESULTS
PATIENTS
From October 1987 to April 1990, 51 newly diagnosed adult patients with ALL or LBL aged 15-75 years were registered from 17 institutions before beginning treatment and 46 (90%) of them were eligible and evaluable (Table 2 ). During the initial 2 years, patient registration was done at the study chair office, then it was passed to the JCOG Data Center (28) in 1991. One patient with T-ALL and a bulky mediastinal mass had received emergent radiation therapy at the time of entry. Another patient had received low-dose glucocorticoids by the referring physician. These two patients were judged to be eligible, because they had not received anticancer agents. Five patients (10%) were ineligible for the following reasons; one patient was initially diagnosed as having 'myeloperoxidase-negative ALL', but the diagnosis was later changed to AML (MO), because an immunophenotypic analysis revealed that myeloid antigen (CD13) was positive and that B-or T-Iymphoid antigens were negative. One patient was ineligible because of the complication of schizophrenia. In the remaining three patients, various preceding chemotherapies had been given. An imrnunophenotypic analysis was successfully performed in all 46 eligible patients (Table 3) . There were no patients showing the mature B-cell phenotype (Burkitt type B-ALL). Surface expression of at least one B-lineage antigen was observed in 26 patients (57%), consisting of 22 patients (48%) showing the pure B-lineage and four (9%) the mixed lineage phenotype; TIE in two cases and B/myeloid in two. Seventeen patients (37%) expressed at least one T-lineage antigen, consisting of 15 (33%) cases of the pure T-lineage and two (4%) of mixed phenotype coexpressing Tand B-Iymphoid antigens. In subgroup analysis, the 15 patients showing pure T-lineage were categorized as T-cell phenotype and the remaining 31 patients as non-T-cell phenotype. It was reported from participating institutions that a Philadelphia (Ph) chromosome was identified in three patients; two patients showed the B-lineage phenotype and one the mixed phenotype coexpressing T-and B-Iymphoid antigens. In one T-ALL patient, leukemic cells expressed the yilT-cell receptor. In another T-ALL patient, the leukemic cells showed a phenotypic change to myeloid phenotype (AML) at relapse. Months from the beginning of chemotherapy Figure 1 . Overall survival of all 46 eligible patients with ALL or LBL treated in JCOG study 8702 is shown after a median follow-up time of96 months. The estimated probability of survival at 7 years is 15%.
PATIENT CHARACTERISTICS AND THERAPEUTIC RESULTS
Thirty-six (78%, 95% confidence interval 64-89%) of the 46 eligible patients achieved CR. Their median age was 35 years, ranging from IS to 74 years. Eighteen patients (39%) were younger than 30 years, 22 (48%) were 30-59 years old and six (13%) were 60 years or older. There were 25 men (54%) and 21 women (46%). Five patients (11%) were clinically diagnosed as having LBL and all of them showed the T-cell phenotype. The remaining 41 patients (89%) were diagnosed as having ALL. Eight patients (17%) had a bulky mediastinal mass and the immunophenotype of its neoplastic cells was the T-cell type in seven patients and the undifferentiated type in one. The initial leukocyte count ranged from 1000 to 237 500lJlI (median, 120001JlI) and platelet counts ranged from 2000 to 334 OOOIJlI (median, 113 OOO/J..lI). Twenty-five patients (54%) had a leukocyte count ;;::100001f.ll, 10 (22%) had a leukocyte count >30 OOOIJlI and two (4%) had hyperleukocytosis with a leukocyte count>100 OOOIJll. As shown in Table 2 , one patient with ALL died of pneumonia during prolonged neutropenia after undergoing induction chemotherapy (VEPA-L), without achieving CR. Among the 36 patients who achieved CR, four patients (11%) died in CR, 26 (72%) relapsed and the remaining six (17%) were alive in the first CR at the time of last follow-up. Causes of deaths observed in CR were as follows: one patient died of fulminant hepatitis caused by the activation of hepatitis B virus after receiving two courses of VEPA-L and two patients died of interstitial pneumonia while undergoing M-VEPA therapy. One patient with ALL underwent allogeneic bone marrow transplantation (BMT) from his HLAidentical sibling donor; however, he died ofveno-occlusive disease 44 days after the BMT. Most of the relapsed patients showed BM relapse, but at least three patients showed eNS relapse.
The overall survival of all 46 eligible patients at a median follow-up time of 96 months is shown in Fig. 1 . The median 
Months from the beginning of chemotherapy The numbers of patients who developed non-hematologic toxicities of grade 3 or more except for alopecia and nausea! vomiting during treatment are shown in Table 5 . The major non-hematological toxicities of grade 3 or more encountered in the patients receiving VEPA-L were hepatic dysfunction (22%, 10/46), infection (15%, 7/46) and peripheral neuropathy (7%, 3/46). Among the 39 patients treated with M-VEPA, five patients (13%) developed hepatic dysfunction and four (10%) developed peripheral neuropathy of grade 3 or more. Three (8%) of the 39 patients treated with M-VEPA developed interstitial pneumonia and two of them died of respiratory failure.
survival for all 46 eligible patients was 14 months. The estimated probability of survival at 7 years is 15%. Among the 46 eligible patients, 39 patients (85%) died and seven (15%) were alive at the time ofthe last follow-up (August 15, 1996) . The DFS rate ofthe 36 patients who achieved CR is shown in Fig. 2 . The median DFS for the 36 patients achieving CR was 11 months and their estimated probability of DFS at 7 years is 17% at a median follow-up time of 93 months. Thus, in all 46 eligible patients, the estimated probability of DFS at 7 years is 13%.
SUBGROUP ANALYSIS
The CR rates were compared between subsets according to the following 14 variables; age «30 vs~30), sex (female vs male), WHO PS (0, I vs 2-4), erythrocytes «3 x I 06/J-ll vs~3 x 10 6/J-ll), leukocytes «10 000/J-l1 vs~10 OOO/J-ll), granulocytes «8000/J-l1 vs~8000/J-ll), platelets «100 000/J-l1 vs~100 OOO/J-ll), immunophenotype of neoplastic cells (non-T vs T), B-symptom (absent vs present), lactic dehydrogenase (LDH) (normal vs elevated), GOT (normal vs elevated), C-reactive protein (CRP) (normal vs elevated), neoplastic cells in PB (absent vs present) and clinical diagnosis (ALL vs LBL). However, significant factors influencing CR-rates (P < 0.05) were not identified.
Small P-values by the log-rank test were obtained in the following subsets: an elevated level of CRP vs normal level (P = 0.001) (Fig. 3) , age of 30 years or older vsyounger (P = 0.004) (Fig. 4) and the presence vs absence ofB-symptom (P = 0.019).
In case of CRP level, the P-value can be considered as statistically significant even after Bonferroni correction (a = 0.0035) (29) .
Cox proportional hazards regression analysis also showed that T-cell phenotype (risk ratio 4.360, P =0.013), B-symptom (risk ratio 3.289, P = 0.034), older age (risk ratio 3.184, P = 0.035) and an elevated CRP (risk ratio 3.070, P =0.045) were likely to be associated with shortened survival, although there was no strongly significant association (Table 4) . (34, 35) . Therefore, the CR rate of the present study, 78% (95% confidence interval 64-89%), is as satisfactory as that of a multi-institutional study. However, the long-term survival rates of ALL and LBL in adults have been reported from Western countries to range from 20 to 35% (1, (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (30) (31) (32) (33) (36) (37) (38) . The low long-term survival rate in the present study (15%), the short duration of median survival (14 months) and the median DFS (11 months) are not satisfactory. It has been reported that older age, presence of Ph chromosome, high leukemic cell count, longer time to achieve CR and non-T-cell immunophenotype are prognostic factors of adult ALL associated with shortened survival (4, 6, 10, 12, 13, 18, (33) (34) (35) 39, 40) . Among these, age is known to be a strong prognostic factor (4, 6, 10, 12, 13, 18, 34, 35, 41) . Good outcomes are more likely in young ALL patients (41) . Most chemotherapy trials against adult ALL conducted in Western countries reported that the median ages of the patients were in the twenties (12) . However, the median ages in patients with adult ALL or LBL entered into Japanese multi-institutional studies were fairly high; 35 years in the present study and 38 and 43 years in the recently published JALSG studies (34, 35) . The prognosis of LBL is also strongly governed by age (1, 38) . Therefore, the low survival rate observed in the present study may be partially related to the relatively high median age (35 years).
The anticancer agents we used in the present study (VCR, CPM, PSL, DXR, l-asp and MTX) are all standard agents for ALL (6, 10, 12, 13) . There are three recent studies (5, 33, 36) in which the patients' median age was in the thirties. All three of these studies included cytosine arabinoside (ara-C) and two (5, 36) of them used high-dose ara-C in consolidation or intensification. The CALGB 8811 study (33) included a subcutaneous administration of ara-C at a conventional dose and the remaining two studies (5,36) used etoposide or mitoxantrone in induction therapy.
Remission maintenance therapy has been incorporated not only in pediatric ALL studies but also in adult ALL studies, although its benefit has not been established in adults. The most frequently used maintenance therapy consists of daily 6-MP and weekly MTX with monthly pulses of VCR and PSL for 1-3 years (13) . Some recent studies revealed that omission of maintenance therapy after the completion of consolidation therapy resulted in short DFS periods (42) (43) (44) . In the CALGB 85 I3 study, treatment was completed after 29 weeks and the median remission duration was only 11 months (42) . This was markedly shorter than the 21 months in the earlier CALGB study 8011 incorporating 3 years of maintenance therapy (45). Cassileth et al. (43) reported the results of ECOG studies 2483 and 3486 in which therapy was completed after a 12-month consolidation without maintenance therapy. The median DFS periods of the ECOG studies were only 9-11 months (43). Furthermore, a Dutch group recently reported the results of intensive post-remission therapy including highdose ara-C without maintenance therapy (44) . They concluded that intensive consolidation without maintenance therapy provides an outcome that may be inferior compared with studies using prolonged maintenance therapy. Hence it is likely that the high relapse rate (72%) among the patients achieving CR in the present study is due to the lack of a conventional prolonged maintenance therapy.
Based on the recent studies of adult ALL and LBL, more intensive consolidation chemotherapy, the addition of non-crossresistant agents and the incorporation of conventional maintenance therapy using oral6-MP and MTX may improve long-term survival rates (13) .
In the present study, 72% of the patients who achieved CR relapsed. Most of them showed BM relapse, but at least three of them showed CNS relapse. In this JCOG 8702 study, to prevent CNS relapse, four intrathecal administrations of MTX and four intravenous administrations of intermediate-dose (400 mg/m-) MTX were scheduled. Since systemic relapse occurred frequently' it seems very difficult to evaluate the efficacy of the CNS-prophylactic measures in the present study. The recent investigation conducted in the M.D. Anderson Cancer Center suggested that high-dose systemic chemotherapy and early intrathecal chemotherapy were useful prophylactic measures against CNS leukemia and thata risk-oriented approach would be appropriate to tailor the intensity of CNS prophylaxis (46) .
The present study suggests that CRP level may be a new prognostic factor in adult ALL and LBL, a finding which has not been described previously, to our knowledge. In multiple myeloma, an elevated level of CRP is reported to be an unfavorable prognostic factor correlated with the interleukin (IL)-6 level (47) . It has also been reported that the CRP level is an independent prognostic factor for the survival of melanoma patients treated with IL-2-based immunotherapy (48) . Since patients with severe infection at diagnosis were excluded from the present study, the high CRP level may indicate tumor aggressiveness related to the presence of B-symptom or the production of a cytokine such as IL-6.
In summary, we have reported the results of a multi-institutional study of a short-term simplified combination chemotherapy without the traditional use of a maintenance therapy in adult patients with ALL or LBL, conducted by the JCOG-LSG. Although the CR rate is within the range of satisfaction (78%, 36/46) compared with that of a multi-institutional study, the long-term survival rate (15%) is disappointing. The high relapse rate (72%, 26/36) in the present study suggests that the post-remission therapy is not adequate and cannot substitute for a conventional long-term maintenance therapy. Subgroup analysis showed that an elevated serum CRP level, age of 30 years or older, the presence of B-symptom and T-cell phenotype were likely to be associated with shortened survival. To improve the therapeutic results of adult ALL and LBL, further efforts such as the intensification of consolidation therapy, the incorporation of prolonged maintenance therapy and more effective CNS prophylaxis and the introduction of hematopoietic stem cell transplantation are needed.
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